25.67 0.00 (0.00%)
After hours: 4:00PM EDT
|Bid||25.62 x 1200|
|Ask||25.64 x 1000|
|Day's range||25.08 - 25.97|
|52-week range||16.87 - 33.97|
|Beta (5Y monthly)||0.47|
|PE ratio (TTM)||28.30|
|Earnings date||25 Aug 2020 - 31 Aug 2020|
|Forward dividend & yield||0.48 (1.89%)|
|Ex-dividend date||02 Jun 2020|
|1y target est||22.50|
Ladies and gentlemen, thank you for standing by, and welcome to the Phibro Animal Health Corporation Q3 2020 earnings conference. On the call today are Jack Bendheim, our chief executive officer; and myself, Richard Johnson, chief financial officer. Let me remind you that the earnings press release and financial tables can be found on the Investors section of our website at pahc.com.
Phibro Animal Health Corporation (NASDAQ:PAHC) today announced its financial results for its third quarter ended March 31, 2020.
The Board of Directors of Phibro Animal Health Corporation (Nasdaq:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on June 24, 2020, to stockholders of record at the close of business on June 3, 2020.
Phibro Animal Health Corporation (NASDAQ:PAHC) announced today it will participate in the Bank of America Merrill Lynch 2020 Virtual Healthcare Conference.
Phibro Animal Health Corporation (NASDAQ:PAHC) expects to announce its third quarter financial results on Thursday, May 7, 2020, after the market closes. Phibro management will host a conference call and webcast on Friday, May 8, 2020 at 9:00 AM Eastern Time.
The identification of a group of peptides and proteins is a remarkable step toward Phibro's (PAHC) development of a solution for ASF.
Phibro Animal Health Corporation (PAHC) today announced it is pursuing patent protection following a significant advance in the on-going development of a vaccine for African Swine Fever (ASF). This important step in the vaccine development process involves the identification of immunogenic epitopes and proteins that show strong potential to form the basis for a vaccine against ASF.